BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 37715934)

  • 1. Preoperative prediction of pancreatic neuroendocrine tumor grade based on
    Ma J; Wang X; Tang M; Zhang C
    Endocrine; 2024 Feb; 83(2):502-510. PubMed ID: 37715934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CT radiomics may predict the grade of pancreatic neuroendocrine tumors: a multicenter study.
    Gu D; Hu Y; Ding H; Wei J; Chen K; Liu H; Zeng M; Tian J
    Eur Radiol; 2019 Dec; 29(12):6880-6890. PubMed ID: 31227882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accurate non-invasive grading of nonfunctional pancreatic neuroendocrine tumors with a CT derived radiomics signature.
    Javed AA; Zhu Z; Kinny-Köster B; Habib JR; Kawamoto S; Hruban RH; Fishman EK; Wolfgang CL; He J; Chu LC
    Diagn Interv Imaging; 2024 Jan; 105(1):33-39. PubMed ID: 37598013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A radiomic- and dosiomic-based machine learning regression model for pretreatment planning in
    Plachouris D; Eleftheriadis V; Nanos T; Papathanasiou N; Sarrut D; Papadimitroulas P; Savvidis G; Vergnaud L; Salvadori J; Imperiale A; Visvikis D; Hazle JD; Kagadis GC
    Med Phys; 2023 Nov; 50(11):7222-7235. PubMed ID: 37722718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discordance Between Histopathologic Grading and Dual-Tracer PET/CT Findings in Metastatic NETs and Outcome of
    Adnan A; Basu S
    J Nucl Med Technol; 2022 Sep; 50(3):248-255. PubMed ID: 34876476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiomics analysis from magnetic resonance imaging in predicting the grade of nonfunctioning pancreatic neuroendocrine tumors: a multicenter study.
    Zhu HB; Zhu HT; Jiang L; Nie P; Hu J; Tang W; Zhang XY; Li XT; Yao Q; Sun YS
    Eur Radiol; 2024 Jan; 34(1):90-102. PubMed ID: 37552258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites.
    Sadowski SM; Neychev V; Millo C; Shih J; Nilubol N; Herscovitch P; Pacak K; Marx SJ; Kebebew E
    J Clin Oncol; 2016 Feb; 34(6):588-96. PubMed ID: 26712231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
    Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
    J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Impact of 68Ga-DOTATATE PET/CT Imaging on Management of Patients with Neuroendocrine Tumors: Experience from a National Referral Center in the United Kingdom.
    Skoura E; Michopoulou S; Mohmaduvesh M; Panagiotidis E; Al Harbi M; Toumpanakis C; Almukhailed O; Kayani I; Syed R; Navalkissoor S; Ell PJ; Caplin ME; Bomanji J
    J Nucl Med; 2016 Jan; 57(1):34-40. PubMed ID: 26471695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors?
    Has Simsek D; Kuyumcu S; Turkmen C; Sanlı Y; Aykan F; Unal S; Adalet I
    J Nucl Med; 2014 Nov; 55(11):1811-7. PubMed ID: 25315243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The comparison of three different molecular imaging methods in localization and grading of insulinoma.
    Chang L; Bi X; Li S; Tong Q; Gu Y; He Z; Li Y; Chen Q; Cui J; Yu H; He Q; Liu M
    Front Endocrinol (Lausanne); 2023; 14():1163176. PubMed ID: 37455905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The inferior performance of [
    Has Simsek D; Guzel Y; Denizmen D; Sanli Y; Buyukkaya F; Kovan B; Komek H; Isik EG; Ozkan ZG; Kuyumcu S
    Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):828-840. PubMed ID: 37947850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation and Comparison of Somatostatin Receptor Type 2 Immunohistochemical Scoring Systems with 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms.
    Yu J; Cao F; Zhao X; Xie Q; Lu M; Li J; Yang Z; Sun Y
    Neuroendocrinology; 2022; 112(4):358-369. PubMed ID: 34077939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pancreatic neuroendocrine tumor: prediction of tumor grades by radiomics models based on ultrasound images.
    Dong Y; Yang DH; Tian XF; Lou WH; Wang HZ; Chen S; Qiu YJ; Wang W; Dietrich CF
    Br J Radiol; 2023 Sep; 96(1149):20220783. PubMed ID: 37393539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors.
    Deppen SA; Liu E; Blume JD; Clanton J; Shi C; Jones-Jackson LB; Lakhani V; Baum RP; Berlin J; Smith GT; Graham M; Sandler MP; Delbeke D; Walker RC
    J Nucl Med; 2016 May; 57(5):708-14. PubMed ID: 26769865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic
    Yin H; Liu G; Tan H; Shi D; Cheng D; Yu H; Shi H
    Quant Imaging Med Surg; 2023 Sep; 13(9):5555-5567. PubMed ID: 37711843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of initial imaging with gallium-68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors.
    Crown A; Rocha FG; Raghu P; Lin B; Funk G; Alseidi A; Hubka M; Rosales J; Lee M; Kennecke H
    J Surg Oncol; 2020 Mar; 121(3):480-485. PubMed ID: 31853990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New frontiers in imaging including radiomics updates for pancreatic neuroendocrine neoplasms.
    Saleh M; Bhosale PR; Yano M; Itani M; Elsayes AK; Halperin D; Bergsland EK; Morani AC
    Abdom Radiol (NY); 2022 Sep; 47(9):3078-3100. PubMed ID: 33095312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis and staging of small intestinal neuroendocrine tumors with CT enterography and PET with Gallium-68: preoperative risk stratification protocol.
    Bonomi A; Fumagalli Romario U; Funicelli L; Conti G; Realis Luc M; Ceci F; Pozzi S; Radice D; Fazio N; Bertani E
    Langenbecks Arch Surg; 2024 Feb; 409(1):63. PubMed ID: 38363374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.